Company intelligence / Profile preview
Neumora Therapeutics, Inc.
Watertown, Massachusetts, United Statesneumoratx.com ↗
- Ownership
- Public · NMRA
- Development stage
- Other
01
Overview
The company's lead program navacaprant did not meet its primary endpoint in the KOASTAL-1 Phase 3 study for MDD announced in January 2025. The company has paused KOASTAL-2 and -3 studies and plans to resume them in March 2025 with optimized site selection and enhanced medical monitoring. Data from KOASTAL-3 is expected in Q1 2026 and KOASTAL-2 in Q2 2026. The company has discontinued a Phase 2 trial of navacaprant for bipolar depression to prioritize resources for the KOASTAL program.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Financials
- Market cap
- $91.5M
- Total revenue
- $0
- Enterprise value
- $-25M
Beyond the preview
Go deeper on Neumora Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neumora Therapeutics, Inc..